To access this material please log in or register

Register Authorize

Major aspects of using acetylsalicylic acid in clinical practice

Vorobjeva N. M.
Federal State Budgetary Institution, “Russian Cardiology Science and Production Center” of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552

Keywords: cardiovascular diseases, acetylsalicylic acid, treatment

DOI: 10.18087/rhj.2016.1.2169

The review presents major aspects of using acetylsalicylic acid (ASA) in cardiology practice. The author focuses on issues of primary and secondary prevention of CVD and safety of the long-term ASA treatment. The issue of resistance to ASA is discussed in detail. It is shown that in cardiology practice, the most effective and safe chronic treatment should include the buffered ASA form. This ASA form contains, along with the regular ASA, a non-absorbable antacid, which protects the stomach mucosa and, at the same time, does not impair the antiplatelet effect of ASA.
  1. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (IV пересмотр). Кардиоваскулярная терапия и профилактика. 2009;8 (6 Прил 3):1–80.
  2. Панченко Е. П., Добровольский А. Б. Тромбозы в кардиологии. Механизмы развития и возможности терапии. – М.: Спорт и культура, 1999. – 464с.
  3. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 May 30;373 (9678):1849–60.
  4. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324 (7329):71–86.
  5. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of rando­mized controlled trials. JAMA. 2006 Jan 18;295 (3):306–13.
  6. Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk for upper gastrointestinal complications. BMC Med. 2006 Sep 20;4:22.
  7. Rockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ. 1995 Jul 22;311 (6999):222–6.
  8. Wilson R, Gazzala J, House J. Aspirin in primary and secondary prevention in elderly adults revisited. South Med J. 2012 Feb;105 (2):82–6.
  9. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010 Jun 22;121 (24):2694–701.
  10. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009 Nov 6;339: b4531.
  11. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2010 Feb;87 (2):211–8.
  12. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008 Oct 16;337: a1840.
  13. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Jinnouchi H et al. Low-dose aspirin for primary prevention of athe­rosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008 Nov 12;300 (18):2134–41.
  14. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK. Effect of aspirin on vascular and non-vascular outcomes: meta-analysis of randomised controlled trials. Arch Intern Med. 2012 Feb 13;172 (3):209–16.
  15. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009 Mar 17;150 (6):396–404.
  16. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association. Circulation. 2011 Mar 22;123 (11):1243–62.
  17. Подзолков В. И., Перепеч Н. Б., Ощепкова Е. В., Остроумова О. Д., Оганов Р. Г., Никитин Ю. П. и др. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). Кардиоваскулярная терапия и профилактика. 2008;7 (6 Прил 2):1–32.
  18. Halvorsen S, Andreotti F, ten Berg JM, Cattaneo M, Coccheri S, Marchioli R et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol. 2014 Jul 22;64 (3):319–27.
  19. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984 Nov 8;311 (19):1206–11.
  20. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001 Jan;119 (1 Suppl): 39S-63S.
  21. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol. 2003 Mar 19;41 (6):966–8.
  22. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003 Mar 19;41 (6):961–5.
  23. DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007 Dec;56 (12):3014–9.
  24. Neubauer H, Kaiser AF, Endres HG, Kruger JC, Engelhardt A, Lask S et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance – the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.
  25. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003 Jan;2 (1):15–28.
  26. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005 Jun;3 (6):1309–11.
  27. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008 Jan 26;336 (7637):195–8.
  28. Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events – a meta-analysis. Int J Cardiol. 2008 Aug 18;128 (2):166–71.
  29. Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013 Jan 22;127 (3):377–85.
  30. Панченко Е. П., Явелов И. С., Гиацианский Н. А., Кропачёва Е. С., Аверков О. В., Барбараш О. Л. и др. Атеротромботическая терапия у больных со стабильными проявлениями атеротромбоза. Рекомендации Всероссийского научного общества кардиологов и Национального общества по атеротромбозу. Кардиоваскулярная терапия и профилактика. 2009;8 (6 Прил 6):1–26.
  31. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patient without Coronary or other Atherosclerotic Vascular Diseases. Circulation. 2002 Jul 16;106 (3):388–91.
  32. Насонов Е. Л., Каратеев А. Е. Поражения желудка, связанные с приёмом нестероидных противовоспалительных препаратов. Клиническая медицина. 2000;78 (4):4–9.
  33. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs – differences and similarities. N Engl J Med. 1991 Jul 13;324 (24):1716–25.
  34. Wallace JL, McKnight GW. The mucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin. Gastroenterology. 1990 Aug;99 (2):295–304.
  35. Somasundaram S, Hayllar H, Rafi S, Wrigglesworth JM, Macpherson AJ, Bjarnason I. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and hypothesis. Scand J Gastroenterol. 1995 Apr;30 (4):289–99.
  36. Endo H, Hosono K, Inamori M, Kato S, Nozaki Y, Yoneda K et al. Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion. 2009;79 (1):44–51.
  37. Endo H, Sakai E, Higurashi T, Yamada E, Ohkubo H, Iida H et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis. 2012 Oct;44 (10):833–8.
  38. Hirata Y, Kataoka H, Shimura T, Mizushima T, Mizoshita T, Tanida S et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol. 2011 Jul;46 (7-8):803–9.
  39. Баркаган З. С., Котовщикова Е. Ф. Сравнительный анализ основных и побочных эффектов различных форм ацетилсалициловой кислоты. Клиническая фармакология и терапия. 2004;13 (3):1–4.
  40. Верткин А. Л., Аристархова О. Ю., Адонина Е. В., Галкин И. В., Коцелапова Э. Ю. Безопасность и фармакоэкономическая эффективность применения различных препаратов ацетилсалициловой кислоты у пациентов с ИБС. Русский медицинский журнал. 2009;17 (8):570–5.
  41. Яковенко Э. П., Краснолобова Л. П., Яковенко А. В., Агафонов Н. А., Иванов А. Н., Богомолова Е. А. и др. Влияние препаратов ацетилсалициловой кислоты на морфофункциональное состояние слизистой оболочки желудка у кардиологических пациентов пожилого возраста. Сердце. 2013;12 (3):148–53.
  42. Ломакин Н. В., Русанова А. В., Бурячковская Л. И., Вершинина М. Г. Сравнение антиагрегантной эффективности разных форм ацетилсалициловой кислоты. Сердце. 2014;78 (4):206–15.
  43. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991 Oct 31;325 (18):1261–6.
  44. Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: randomised controlled trial. Lancet. 1999 Jun 26;353 (9171):2179–84.
  45. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med. 2002 Oct 24;347 (17):1309–17.
Vorobjeva N. M. Major aspects of using acetylsalicylic acid in clinical practice. Russian Heart Journal. 2016;15 (1):24–33

To access this material please log in or register

Register Authorize
Ru En